PP
AEGR

PDT Partners’s Aegerion Pharmaceuticals AEGR Stock Holding History

PDT Partners’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-69,200
Closed -$256K – 633
2016
Q1 		$256K Sell
69,200
-1,028
-1% -$6.37K 0.02% 486
2015
Q4 		$709K Sell
70,228
-33,058
-32% -$398K 0.1% 245
2015
Q3 		$1.41M Buy
103,286
+24,386
+31% +$434K 0.03% 595
2015
Q2 		$1.5M Buy
+78,900
New +$1.71M 0.04% 572
2013
Q4 		– Sell
-66,660
Closed -$5.71M – 1393
2013
Q3 		$5.71M Buy
+66,660
New +$5.65M 0.15% 161

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

PDT Partners's AEGR Position: Q2 2016 in Review

PDT Partners sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 69,200 shares — an estimated $256K sold.

PDT Partners first reported a position in AEGR in Q3 2013 and held it in 5 quarters. The position peaked at $5.71M in Q3 2013. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

  • PDT Partners reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
  • PDT Partners sold 69,200 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $256K.
  • PDT Partners first reported a position in Aegerion Pharmaceuticals in Q3 2013 and held it in 5 quarters.
  • PDT Partners's Aegerion Pharmaceuticals position peaked at $5.71M in Q3 2013.
  • 71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on PDT Partners's 13F filing for Q2 2016, filed 15 Aug 2016.